About US
Contact us
-
NICE rejects NHS use of Roche’s Ocrevus for PPMSIn its final draft guidance, the UK’s pricing regulator the National Institute of Health and Care Excellence (NICE) has not recommended Roche’s Ocrevus (ocrelizumab) for routine National Health Servic2018/9/14
-
UK researchers develop non-antibiotic drug for tuberculosisResearchers at the University of Manchester have formulated a non-antibiotic drug for the treatment of infection caused by Mycobacterium tuberculosis bacteria (MptpB), including antibiotic resistant s2018/9/14
-
Janssen’s Invokana and Vokanamet receive expanded labelling in EuropeThe European Commission (EC) has approved expanded labelling of Janssen Pharmaceutical’s Invokana and Vokanamet to include positive cardiovascular outcomes. Invokana (canagliflozin) obtained the Euro2018/9/13
-
FDA seeks more clinical data on GSK’s mepolizumab for COPDThe US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to GlaxoSmithKline (GSK)’s application for approval of its pulmonary drug mepolizumab to treat chronic obstructive2018/9/13
-
Consort to develop delivery device for opioid overdose drugUK-based Consort Medical has signed a contract to develop a new drug delivery device for US-based Opiant Pharmaceuticals’ OPNT003 therapeutic intended to treat an opioid overdose. The partners will w2018/9/12
-
Federal court invalidates Acorda’s patents covering MS drug AmpyraThe US Court of Appeals for the Federal Circuit has invalidated four patents held by biopharmaceutical company Acorda Therapeutics covering multiple sclerosis drug Ampyra (dalfampridine). The ruling2018/9/12
-
Study links common arthritis drug azathioprine to skin cancerA joint study by UK universities has revealed a correlation between commonly used arthritis drug azathioprine and the development of skin cancer. The research was conducted by the University of Dunde2018/9/11
-
Pfizer and Merck drug therapy improves PFS in kidney cancer patientsPfizer and Merck reported positive top-line results from the Phase III JAVELIN Renal 101 clinical trial conducted to assess the cominbation of Bavencio (avelumab) and Inlyta (axitinib) as initial ther2018/9/11
-
Chi-Med’s fruquintinib gets approval for colorectal cancer in ChinaHutchison China MediTech (Chi-Med) has secured approval from the National Medical Products Administration of China (NMPA) for the use of fruquintinib capsules to treat metastatic colorectal cancer (CR2018/9/10
-
Teva returns laquinimod global rights to Active BiotechTeva Pharmaceutical Industries has returned global development and commercialisation rights to drug candidate laquinimod to Swedish biotechnology company Active Biotech. The move follows Teva’s decis2018/9/10